Drug Profile
DS 5573a
Alternative Names: DS-5573; DS-5573aLatest Information Update: 19 May 2017
Price :
$50
*
At a glance
- Originator Daiichi Sankyo Company
- Class Antibodies; Antineoplastics
- Mechanism of Action CD276 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 01 May 2017 Discontinued - Phase-I for Solid tumours (Metastatic disease) in Japan (IV) (Daiichi Sankyo pipeline, May 2017)
- 01 Jan 2017 Daiichi Sankyo terminates a phase I trial in Solid tumours (Metastatic disease) in Japan (IV) (NCT02192567)
- 14 Jul 2014 Daiichi Sankyo plans a phase I trial for Solid tumours in Japan (NCT02192567)